Among the combination therapies, targeting aberrant oncogenic signaling pathways, including the MAPK, PI3K–AKT–mTOR, and JAK–STAT pathways, in cancer cells has been shown to increase the efficacy of ICB in preclinical and clinical studies [45]. Here, AKT1 is linked to cancer.